In summary, our findings shed light on the molecular pathways involved in transitioning from benign to pre-malignant stages in BC development, highlighting the potential role of miR-1297 and EphA2 as therapeutic targets or biomarkers for early detection and intervention. This evidence concerns the gene EPHA2 and breast cancer.